Bio-gate AG (BIG1) - Net Assets
Based on the latest financial reports, Bio-gate AG (BIG1) has net assets worth €1.79 Million EUR (≈ $2.09 Million USD) as of December 2024. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€3.95 Million ≈ $4.61 Million USD) and total liabilities (€2.16 Million ≈ $2.52 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read BIG1 liabilities breakdown for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €1.79 Million |
| % of Total Assets | 45.29% |
| Annual Growth Rate | 3.61% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 73.06 |
Bio-gate AG - Net Assets Trend (2020–2024)
This chart illustrates how Bio-gate AG's net assets have evolved over time, based on quarterly financial data. Also explore BIG1 current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for Bio-gate AG (2020–2024)
The table below shows the annual net assets of Bio-gate AG from 2020 to 2024. For live valuation and market cap data, see Bio-gate AG (BIG1) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €1.79 Million ≈ $2.09 Million |
-48.21% |
| 2023-12-31 | €3.45 Million ≈ $4.03 Million |
-18.85% |
| 2022-12-31 | €4.25 Million ≈ $4.97 Million |
+12.78% |
| 2021-12-31 | €3.77 Million ≈ $4.41 Million |
+143.12% |
| 2020-12-31 | €1.55 Million ≈ $1.81 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Bio-gate AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 559332497.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €15.27 Million | 873.08% |
| Total Equity | €1.75 Million | 100.00% |
Bio-gate AG Competitors by Market Cap
The table below lists competitors of Bio-gate AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Loyal Solutions AS
ST:LOYAL
|
$5.32 Million |
|
Krakatoa Resources Ltd
AU:KTA
|
$5.32 Million |
|
Rostra AG
F:3330
|
$5.32 Million |
|
Nikola Corp
NASDAQ:NKLA
|
$5.32 Million |
|
WF Holding Limited Ordinary Shares
NASDAQ:WFF
|
$5.32 Million |
|
XiDeLang Holdings Ltd
KLSE:5156
|
$5.31 Million |
|
Llama Group S.A.
PA:ALLAM
|
$5.30 Million |
|
Palred Technologies Limited
NSE:PALREDTEC
|
$5.30 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bio-gate AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,370,129 to 1,748,440, a change of -1,621,690 (-48.1%).
- Net loss of 1,621,690 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-1.62 Million | -92.75% |
| Other Changes | €0.00 | +0.0% |
| Total Change | €- | -48.12% |
Book Value vs Market Value Analysis
This analysis compares Bio-gate AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.75x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 3.12x to 3.75x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | €0.23 | €0.71 | x |
| 2021-12-31 | €0.48 | €0.71 | x |
| 2022-12-31 | €0.49 | €0.71 | x |
| 2023-12-31 | €0.36 | €0.71 | x |
| 2024-12-31 | €0.19 | €0.71 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bio-gate AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -92.75%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -22.99%
- • Asset Turnover: 1.79x
- • Equity Multiplier: 2.26x
- Recent ROE (-92.75%) is below the historical average (-50.16%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -51.59% | -15.68% | 1.55x | 2.12x | €-960.88K |
| 2021 | -14.84% | -8.73% | 1.20x | 1.42x | €-910.67K |
| 2022 | -43.50% | -30.15% | 0.96x | 1.50x | €-2.22 Million |
| 2023 | -48.12% | -22.38% | 1.38x | 1.56x | €-1.96 Million |
| 2024 | -92.75% | -22.99% | 1.79x | 2.26x | €-1.80 Million |
Industry Comparison
This section compares Bio-gate AG's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $6,173,142,474
- Average return on equity (ROE) among peers: 2.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bio-gate AG (BIG1) | €1.79 Million | -51.59% | 1.21x | $5.32 Million |
| SCHOTT Pharma AG & Co. KGaA (1SXP) | $792.27 Million | 18.89% | 0.82x | $2.39 Billion |
| RENAU.UNSP.ARD 1/5 EO-20 (56S0) | $4.02 Billion | 4.35% | 1.05x | $16.46 Billion |
| MEDIMI AB AK (79T) | $15.24 Million | -107.34% | 0.16x | $427.04K |
| TEVANO SYSTEMS HLDGS INC. (7RBA) | $-736.70K | 0.00% | 0.00x | $210.67K |
| STEVANATO GROUP SPA O.N. (87N) | $841.66 Million | 15.96% | 0.69x | $831.06 Million |
| Carl Zeiss Meditec AG (AFX) | $1.42 Billion | 11.27% | 0.43x | $2.23 Billion |
| CARL ZEISS MEDITEC ADR 1 (AFXA) | $2.03 Billion | 14.48% | 0.39x | $2.14 Billion |
| COLOPLAST SP.ADR 1/10 DK1 (CBH) | $8.29 Billion | 56.75% | 3.52x | $12.73 Billion |
| ESSILORLUXOTTICA 1/2/O.N. (ESLC) | $38.15 Billion | 5.64% | 0.59x | $93.24 Billion |
About Bio-gate AG
Bio-Gate AG provides technologies and customized solutions for health and hygiene in Germany. The company offers HyProtect, a plasma coating which protects the surfaces of medical implants against bacterial colonization; and MicroSilver BG, an elemental microporous silver additive. It distributes its products to veterinarians and veterinary clinics. The company was incorporated in 2005 and is bas… Read more